Reference : Endoprotheses coronaires pharmaco-actives chez les patients diabetiques.
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
Human health sciences : Endocrinology, metabolism & nutrition
Endoprotheses coronaires pharmaco-actives chez les patients diabetiques.
[en] Coronary drug-eluting stents in diabetic patients
Nyssen, Astrid mailto [Université de Liège - ULiège > > > > > 3 doc medecine >]
Legrand, Victor mailto [Centre Hospitalier Universitaire de Liège - CHU > > Cardiologie >]
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Revue Médicale Suisse
Yes (verified by ORBi)
[en] Coronary Artery Disease/etiology/surgery ; Coronary Stenosis/etiology/surgery ; Diabetes Complications/surgery ; Drug-Eluting Stents ; Humans
[en] In diabetic patients, the use of drug-eluting stents (paclitaxel-PES or sirolimus-SES) reduces the risk of restenosis as compared to bare-metal stents. However, the risk of (very) late thrombosis is higher with drug-eluting stents than with bare-metal stents. All together, the incidence of major cardiovascular events is reduced with drug-eluting stents, mainly resulting from a diminution of revascularisation procedures rather than from a reduction in myocardial infarcts or cardiovascular deaths. Attempts to compare SES and PES gave discordant results in both randomised trials and registries. Efficacious antiplatelet therapy in the long run is mandatory in all diabetic patients treated with drug-eluting stents.
Researchers ; Professionals ; Students
Tous nos remerciements à Médecine &Hygienne

File(s) associated to this reference

Fulltext file(s):

Open access
Endoprothèses coronaires.pdfAuthor postprint66.39 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.